Short answer
MBX Biosciences, Inc. (MBX) filed an 8-K current report with the SEC on October 22, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Peter Radovich appointed independent director effective October 20, 2026, expanding the Board to eight members.
MBX Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Peter Radovich appointed independent director effective October 20, 2026, expanding the Board to eight members
- Class I director term runs through the 2028 Annual Meeting, supporting near-term board continuity
- Initial equity award: non-qualified option for 18,200 common shares
- Additional cash compensation under MBX’s amended Non-Employee Director Compensation Policy
- Indemnification agreement matches arrangements for existing directors, with no disclosed related-party transactions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MBX Biosciences, Inc. 8-K filings
Get the next MBX 8-K as it lands
Follow MBX for push alerts, or ask the research agent what this filing means.